Feb 20, 2024
AMTAGVI™ is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. PHILADELPHIA, PA. February 20, 2024 – WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the...
Nov 8, 2023
SHANGHAI, November 8, 2023 – WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO) congratulates its customer, Juventas Cell Therapy, on achieving China’s NMPA approval for Juventas’ New Drug Application...
Aug 22, 2023
– Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts – – Partnership for CABA-201 builds on existing manufacturing agreement for clinical...